Kolexia
Venat Laurence Oncologie médicale
Venat Laurence
Oncologie médicale
Hôpital Dupuytren
Limoges, France
135 Activités
2 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de l'ovaire Prédisposition génétique à une maladie Carcinome épithélial de l'ovaire Récidive tumorale locale Carcinomes Seconde tumeur primitive Métastase tumorale Cellules tumorales circulantes

Collaborateurs

Voir plus
Lortholary Alain
Lortholary Alain
Alek Onco, Nantes, France
Mouret-Reynier Marie-Ange
Mouret-Reynier Marie-Ange
Centre Jean-Perrin, Clermont-Ferrand, France
Dalenc Florence
Dalenc Florence
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Tubiana-Mathieu Nicole
Tubiana-Mathieu Nicole
Hôpital Dupuytren, Limoges, France

Industries

Voir plus
A+A
14 collaboration(s)
Dernière en 2023
AstraZeneca
12 collaboration(s)
Dernière en 2023
Novartis
6 collaboration(s)
Dernière en 2022
Zeste Research
4 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast cancer research and treatment   07 mars 2024
POLAR: A Phase III Open-label, Multicenter, Randomized Trial of Adjuvant Palbociclib in Combination With Endocrine Therapy Versus Endocrine Therapy Alone for Patients With Hormone Receptor Positive / HER2-negative Resected Isolated Locoregional Recurrence of Breast Cancer
Essai Clinique (Pfizer)   05 mars 2024
COVAR: Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic Counseling
Essai Clinique (Institut Curie)   16 janvier 2024
NeoTOP: Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer
Essai Clinique (Unicancer)   06 décembre 2023
PembroSCCOHT: Multicentric Non-randomized Phase II of Pembrolizumab in Combination With Etoposide-cisplatin-based Chemotherapy in First-line Small Cell Ovarian Carcinoma of Hypercalcemic Type
Essai Clinique (Merck & Co.)   17 novembre 2023
OPALINE: AN OBSERVATIONAL REAL-WORLD STUDY OF THE SYSTEMIC TREATMENT OF WELL-DIFFERENTIATED, UNRESECTABLE OR METASTATIC, PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOURS (PNET): A STUDY OF MORBIDITY AND MORTALITY AT 2 YEARS
Essai Clinique (Pfizer)   09 novembre 2023
CHIVA: Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
BFR-ESS: Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS
Essai Clinique (Centre Léon-Bérard)   31 août 2023
Physician compliance with multidisciplinary tumor board recommendations for managing gynecological cancers.
Future oncology (London, England)   26 mai 2023
131P Efficacy of neoadjuvant letrozole and palbociclib in HER2-low vs HER2 zero luminal breast cancer: An analysis of the Unicancer Neopal phase II study
Abstract Book of ESMO Breast Cancer 2023, Berlin, Germany, 11-13 May 2023   01 mai 2023